Circulating surfactant protein-D as a biomarker of severity in stable chronic obstructive pulmonary diseases

Zaky, Doaa Zakaria; Naiem, Mona; Eid, Hoda A.; Adawy, Zeinab; Abd-Elraheem, Sabah E.; Mohamed, Zakia

doi:10.1016/j.ejcdt.2014.03.011

Cited by 7 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…C-reactive protein levels of 2,896.89 Ϯ 1,739.76 ng/mL in subjects with normal lung function (see Table 4) are similar to those reported by Akbulut et al 74 SPD, found predominantly in the endoplasmic reticulum of type-2 alveolar cells and in the secretory granules of Club cells in lungs, 36 has the highest expression in the distal airways and alveoli in human tissues and plays a central role in pulmonary host defense. 77 SPD levels of 74.84 Ϯ 30.33 ng/mL in control subjects is in agreement with results obtained by Janssen et al 78 The increased SPD levels in subjects with COPD is in agreement with results of Lomas et al, 79 who found serum SPD to be a biomarker of COPD in the ECLIPSE cohort, Zaky et al, 80 who suggested SPD as a promising biomarker for severity in stable subjects with COPD, and Liu et al, 81 who reported significantly increased serum SPD levels in a COPD group compared with a control group. Sin et al 82 found that FEV 1 was inversely associated with serum SPD levels, but not with Club cell protein 16, and reported that circulating SPD levels may be useful biomarkers to track health outcomes in subjects with COPD.…”

Section: Discussionsupporting

confidence: 87%

Diagnostic Utility of Biomarkers in COPD

Ambade¹,

Sontakke

Barthwal³

et al. 2015

Respir Care

View full text Add to dashboard Cite

BACKGROUND: COPD will become the third leading cause of death by 2020. There are many situations in which spirometry, the primary tool for diagnosis of COPD, cannot be performed, and thus, the staging and status of these patients cannot be determined. To date, there is no known biochemical marker used for diagnosing COPD. This study aimed to explore the utility of biomarkers for diagnosis of COPD. METHODS: This was an observational study composed of 96 stable subjects with COPD and 96 subjects with normal lung function. Each group contained an equal number of smokers and nonsmokers. Serum levels of superoxide dismutase 3, glutathione peroxidase, catalase, ceruloplasmin ferroxidase activity, C-reactive protein, and surfactant protein D (SPD) were estimated. Ferroxidase activity was estimated by a kinetic method, whereas the other analytes were measured by enzyme-linked immunosorbent assay. The cutoff value, sensitivity and specificity at the cutoff value, and area under the curve for each analyte were determined from receiver operating characteristic curve. RESULTS: Significantly decreased superoxide dismutase 3 and increased ferroxidase activity, SPD, glutathione peroxidase, and C-reactive protein levels were found in subjects with COPD. For all subjects and nonsmoking subjects with COPD, the area under the curve was highest for ferroxidase activity, followed by glutathione peroxidase, SPD, and C-reactive protein, with a sensitivity and specificity of > 73%. For smoking subjects with COPD, the area under the curve was highest for SPD, followed by glutathione peroxidase, ferroxidase activity, and C-reactive protein, with a sensitivity and specificity > 67%. Some combinations of markers were found to give either a sensitivity or specificity of > 95%, which can be utilized to rule in and rule out COPD. CONCLUSIONS: Biomarkers can be reliably utilized in the diagnosis of COPD. Of all the markers, SPD appears to be the most promising in smokers, whereas ferroxidase activity shows promise in nonsmokers. To rule out COPD, ferroxidase activity or glutathione peroxidase can be potentially useful, whereas to rule in COPD, ferroxidase activity and glutathione peroxidase appear to be the most promising combination in both nonsmoking and smoking subjects.

show abstract

Section: Discussionsupporting

confidence: 87%

Diagnostic Utility of Biomarkers in COPD

Ambade¹,

Sontakke

Barthwal³

et al. 2015

Respir Care

View full text Add to dashboard Cite

show abstract

“…Thus, SP‐D may be useful as a disease severity marker for patients with ILD . Other studies also supported a significant negative correlation between serum SP‐D and FEV 1 in patients with COPD …”

Section: Discussionmentioning

confidence: 83%

“…In addition, serum SP‐D levels were higher in IPF non‐survivors than in IPF survivors . Furthermore, Zaky et al reported that the serum SP‐D level was significantly higher in COPD particularly in stages III and IV compared with stages I and II. Previous studies correlate SP‐D level with management of the underlying lung condition; SP‐D levels increase with acute disease exacerbation and decrease after systemic corticosteroid therapy in patients with IPF, IPCD, and eosinophilic pneumonia in parallel with clinical improvement …”

Section: Discussionmentioning

confidence: 97%

“…One of particular interest is surfactant protein‐D (SP‐D), which is a macromolecular lipoprotein complex synthesized by type II pneumocytes and Clara cells . SP‐D levels in serum may reflect disease activity and therefore, it has been suggested as a potential biomarker for the epithelial integrity in chronic obstructive pulmonary diseases (COPD) . Increased SP‐D serum levels have been reported for lung diseases such as idiopathic pulmonary fibrosis, pulmonary alveolar proteinosis, cystic fibrosis, COPD, and for infectious diseases like tuberculosis and bacterial pneumonia …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Surfactant protein D as a marker for pulmonary complications in pediatric patients with sickle cell disease: Relation to lung function tests

Tantawy

Adly

Ebeid

et al. 2019

Pediatric Pulmonology

View full text Add to dashboard Cite

Background: Surfactant protein D (SP-D) is considered a candidate biomarker for lung integrity and for disease progression. Aim:We determined the level of SP-D in children and adolescents with SCD and assessed its possible relation to pulmonary complications and lung function.Methods: Serum SP-D levels were assessed in 50 SCD patients compared with 30 healthy controls. High-resolution computerized tomography (HRCT) of the chest was done. Forced vital capacity (FVC), forced expiratory volume in 1 s (FEV 1 ), FEV 1 /FVC% and forced expiratory flow rate during 25-75% of expiration (FEF25-75%) were determined.Results: SP-D was significantly higher in SCD patients than controls, particularly patients with sickle cell anemia than those with sickle β-thalassemia. SP-D levels were significantly associated with increasing severity of interstitial lung disease. The highest SP-D levels were observed among patients with restrictive lung disease followed by mixed type then obstructive lung disease. SP-D was positively correlated to HbS and serum ferritin while negatively correlated to duration of hydroxyurea treatment and parameters of pulmonary functions. ROC curve analysis revealed that SP-D cutoff value 720 ng/mL could significantly detect the presence of abnormal pulmonary function among SCD patients with 82% sensitivity and 88% specificity. Logistic regression analysis showed that SP-D is an independent factor related to abnormal pulmonary function in SCD.Conclusions: SP-D may be a promising biomarker for screening of SCD patients for risk of later pulmonary complications. K E Y W O R D S iron overload, pulmonary function tests, sickle cell disease, surfactant protein-D

show abstract

“…Peneliti tersebut mendapatkan tingkat serum SP-D yang lebih tinggi secara bermakna di pasien PPOK GOLD 3-4 yaitu 6,18±3,2 ng/mL dibandingkan dengan PPOK GOLD 1-2 yang mempunyai tingkat SP-D 3,4±1,4 ng/mL (P=0,005). 29 Beberapa orang subjek penelitian menunjukkan tingkat serum SP-D yang rendah di kajian ini. Hal tersebut dapat disebabkan oleh beberapa faktor, antara lain: Heterogenitas subjek penelitian.…”

unclassified

Kadar Surfactant Protein-D Serum Pada Pasien Penyakit Paru Obstruktif Kronis Berkebahayaan Kambuhan Rendah Dan Tinggi

Nurhayati¹,

Parwati²,

Rostini³

et al. 2018

Indonesian J. Clin. Pathol. Med. Lab.

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) cause high morbidity and mortality worldwide. The exacerbations in chronicobstructive pulmonary disease accelerate the decline in lung function and health status, as well as in increasing the treatment cost andmortality risk. The spiro metric measurement has several limitations in assessing the severity as well as the exacerbation risk in COPDpatients. Currently, has been available serum surfactant protein-D, a marker of lung inflammation and lung tissue damage. This proteinis produced by the alveolar type II cells and the Clara cells that play role in maintaining the lung stability and pulmonary immunesystem. The increased level of serum SPD indicates that there is lung epitihelial leakage in line with COPD severity increment and reflectedin COPD exacerbation level of risk according to combined COPD assessment GOLD criteria of the year 2011. The aim of this study wasto know the differences of SP-D serum levels between low and high risk of exacerbation in COPD patients by determination them. Thisstudy was conducted from March to July 2014. The subjects of this study were COPD patients diagnosed by spiro metric measurement.The research was conducted in comparative analytic way with a cross sectional study design. The statistical analysis was performedusing Mann-Whitney non-parametric test. The subjects were 62 COPD patients. The SP-D serum level at low risk of exacerbation groupdiffer significantly compared to the high risk exacerbation group, 1.8–68.4 ng/mL and 3.36–116.4 ng/mL respectively (P=0.018).Based on this study it can be concluded that the SP-D serum levels were higher in COPD patients with high risk exacerbation than thelower risk one. The SP-D serum levels may be considered as a specific marker of lung tissue injury to assess the risk of the exacerbationin COPD patients.

show abstract

Circulating surfactant protein-D as a biomarker of severity in stable chronic obstructive pulmonary diseases

Cited by 7 publications

References 26 publications

Diagnostic Utility of Biomarkers in COPD

Diagnostic Utility of Biomarkers in COPD

Surfactant protein D as a marker for pulmonary complications in pediatric patients with sickle cell disease: Relation to lung function tests

Kadar Surfactant Protein-D Serum Pada Pasien Penyakit Paru Obstruktif Kronis Berkebahayaan Kambuhan Rendah Dan Tinggi

Contact Info

Product

Resources

About